Brief: Compass Therapeutics Q3 basic EPS USD -0.08
09/11/2023 12:39
Nov 9 (Reuters) - Compass Therapeutics Q3 income from operations USD -11.926 million. * Q3 net income USD -9.964 million * Q3 operating expenses USD 11.926 million * Q3 basic EPS USD -0.08
Recent news on Compass Therapeutics
See all newsBrief: Compass Announces Inducement Grants Under Nasdaq Listing Rule
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
U.S. STOCKS ON THE MOVE-Vicor, Thor Industries, Lennar
Brief: Compass Therapeutics Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback